Kaiser P K, Do D V
Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Int J Clin Pract. 2007 Mar;61(3):501-9. doi: 10.1111/j.1742-1241.2007.01299.x.
Age-related macular degeneration (AMD) is the leading cause of adult blindness among individuals aged 50 and older in the Western world, with the neovascular form of AMD responsible for the most severe and rapid visual loss. Although monotherapy with currently available treatments can slow the rate of loss of vision in eyes with neovascular AMD, they do not significantly improve vision. Vascular endothelial growth factor-A (VEGF-A) plays a critical role in the pathogenesis of neovascular AMD, and ranibizumab is a promising new treatment that targets all VEGF-A isoforms and their biologically active degradation products. Clinical trials have reported that ranibizumab treatment resulted in greater proportions of patients achieving a < 15 letter loss of visual acuity and improved vision at 12 and 24 months than control groups. The incidence of serious ocular and systemic adverse events was low in all ranibizumab trials to date. Currently, ranibizumab is the only treatment for neovascular AMD to demonstrate significant improvement in vision for many patients and represents a major advance in treating neovascular AMD.
年龄相关性黄斑变性（AMD）是西方世界50岁及以上成年人失明的主要原因，其中新生血管性AMD导致最严重和最迅速的视力丧失。尽管目前可用的治疗方法进行单一疗法可以减缓新生血管性AMD患者眼睛的视力丧失速度，但它们并不能显著改善视力。血管内皮生长因子-A（VEGF-A）在新生血管性AMD的发病机制中起关键作用，而雷珠单抗是一种有前景的新疗法，可靶向所有VEGF-A异构体及其生物活性降解产物。临床试验报告称，与对照组相比，雷珠单抗治疗使更多患者在12个月和24个月时视力下降<15个字母，并改善了视力。在迄今为止所有的雷珠单抗试验中，严重眼部和全身不良事件的发生率都很低。目前，雷珠单抗是唯一一种能让许多患者视力得到显著改善的新生血管性AMD治疗方法，代表了治疗新生血管性AMD的一项重大进展。
